Why is liraglutide daily rather than weekly?

Its C16 chain binds albumin less strongly than semaglutide's C18 diacid, and it lacks the Aib substitution that blocks DPP-4 directly. Half-life is around 13 hours rather than about a week.

Is liraglutide closer to human GLP-1 than exenatide?

Much closer — about 97% homology against exenatide's 53%. Exenatide is a different peptide that happens to fit the same receptor.

Is liraglutide still relevant?

It has been overtaken clinically, but it established albumin binding as the standard half-life extension strategy that every later compound uses.

GLP-1 & Incretin Science

What Is Liraglutide? The Bridge Generation

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Liraglutide is a GLP-1 analogue with roughly 97% homology to the native hormone, modified with a C16 palmitic acid chain that binds albumin and extends its half-life to around 13 hours — enough for daily dosing. It is the generation between exenatide and semaglutide.

Key facts

Class: GLP-1 receptor agonist (peptide analogue)
Developer: Novo Nordisk
Molecular weight: ~3,751 Da
Molecular formula: C172H265N43O51
PubChem CID: 16134956
Homology to native GLP-1: ~97%
Lipid chain: C16 palmitic acid
Dosing: Once daily

The design step it represents

Exenatide showed that a protease-resistant GLP-1 receptor agonist worked. Liraglutide asked a different question: could the human hormone itself be modified rather than replaced by a lizard peptide? At roughly 97% homology to native GLP-1, it stays much closer to the original sequence than exenatide's 53%, and solves clearance by attaching a fatty acid rather than by substituting the whole molecule.

What the C16 chain does

Palmitic acid attached to the peptide binds reversibly to serum albumin. The bound complex is too large for glomerular filtration and is physically shielded from proteases, while a small free fraction remains available to engage the receptor. The result is a half-life of roughly 13 hours — a very large improvement on one to two minutes, and enough for once-daily dosing.

Why semaglutide went weekly and liraglutide did not

Chain length. Liraglutide uses C16; semaglutide uses a C18 diacid attached through a longer γGlu-2xOEG linker, and also substitutes Aib at position 8 to block DPP-4 directly. Stronger albumin binding plus enzymatic protection moves the half-life from hours to about a week. The two molecules are the same strategy executed at different intensities.

Where it sits now

Liraglutide has been overtaken on effect size and convenience by weekly analogues, and by the dual and triple agonists beyond them. It retains historical significance as the first GLP-1 analogue derived from the human sequence rather than from venom, and as the compound that established albumin binding as the standard route to half-life extension in this class.

The pattern it established

Look at semaglutide, tirzepatide and retatrutide and the same feature appears in each: a fatty diacid chain for albumin binding, with length and linker tuned to the dosing interval required. Liraglutide is where that pattern starts. Understanding it explains the structural family resemblance across compounds targeting quite different receptors.

Quick reference

	Exenatide	Liraglutide	Semaglutide
Origin	Gila monster venom	Human GLP-1 analogue	Human GLP-1 analogue
Homology to GLP-1	~53%	~97%	~94%
DPP-4 resistance	Natural (Gly2)	Partial	Aib8 substitution
Lipid chain	None	C16 palmitic	C18 diacid
Dosing	Twice daily / weekly	Once daily	Once weekly

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why is liraglutide daily rather than weekly?: Its C16 chain binds albumin less strongly than semaglutide's C18 diacid, and it lacks the Aib substitution that blocks DPP-4 directly. Half-life is around 13 hours rather than about a week.
Is liraglutide closer to human GLP-1 than exenatide?: Much closer — about 97% homology against exenatide's 53%. Exenatide is a different peptide that happens to fit the same receptor.
Is liraglutide still relevant?: It has been overtaken clinically, but it established albumin binding as the standard half-life extension strategy that every later compound uses.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum